In vivo assessment of hydroxyapatite and silicate-substituted hydroxyapatite granules using an ovine defect model.
Phase pure hydroxyapatite (HA) and two silicate-substituted hydroxyapatites (0.8 and 1.5 wt% Si, or 2.6 and 4.9 wt% SiO4) were prepared by aqueous precipitation methods. The filter-cakes of HA and silicate-substituted hydroxyapatite (SiHA) compositions were processed into granules 1.0-2.0 mm in diameter and sintered at 1200 degrees C for 2 h. The sintered granules underwent full structural characterisation, prior to assessment in an ovine defect model by implantation for a period of 6 and 12 weeks. The results indicate that HA and SiHA implants were well accepted by the host tissue, with no evidence of inflammation. New bone formation was observed directly on the surfaces and in the spaces between the granular implants. Quantitative histomorphometry as determined by the percentage of bone ingrowth and bone coverage for both SiHA implant compositions was significantly greater than that for phase pure HA. These findings indicate that the in vivo bioactivity of hydroxyapatite was significantly improved by the incorporation of silicate ions into the HA structure, making SiHA ceramics attractive alternatives to conventional HA materials for use as bone graft substitute ceramics.
Patel
N
N
Department of Materials Science and Metallurgy, University of Cambridge, New Museums Site, Cambridge, CB2 3QZ, UK.
Brooks
R A
RA
Clarke
M T
MT
Lee
P M T
PM
Rushton
N
N
Gibson
I R
IR
Best
S M
SM
Bonfield
W
W
D000818:Animals; D018786:Bone Substitutes / Q000737:chemistry* / Q000627:therapeutic use*; D017886:Durapatite / Q000737:chemistry* / Q000627:therapeutic use*; D005264:Femoral Fractures / Q000473:pathology* / Q000628:therapy*; D017102:Fracture Healing; D008422:Materials Testing; D008863:Microspheres; D008970:Molecular Weight; D010316:Particle Size; D012756:Sheep; D017640:Silicates / Q000737:chemistry* / Q000627:therapeutic use*; D016896:Treatment Outcome
D018786:Bone Substitutes; D017640:Silicates; D017886:Durapatite